ProstaScint Fusion Imaging
- A Single-Photon Emission Computed Tomography (SPECT) dataset of the pelvis and abdomen is required (other datasets may be performed if medically indicated)
- Computed Tomography (CT) acquired either on a hybrid camera or separately, preferably on same day as SPECT
- Fused images directly aligned on hybrid cameras or fused via fusion software
- Fusion can also be performed with Magnetic Resonance Imaging (MRI)
ProstaScint is a radio labeled monoclonal antibody – a biologic product that targets a specific antigen. ProstaScint targets Prostate Specific Membrane Antigen (PSMA), a protein uniquely expressed by prostate tissue and up regulated in prostate cancer. Indium 111 Chloride is labeled to the proprietary, murine monoclonal antibody. The radiolabeled antibody is injected into the patient and is taken up by prostate cancer cells, which can be detected and visualized with single-photon emission tomography (SPECT), and is specific for the detection of metastatic lymph node involvement.
ProstaScint Indications for Use:
Indium In 111 ProstaScint (Capromab Pendetide) is indicated as a diagnostic imaging agent in newly-diagnosed patients with biopsy-proven prostate cancer, thought to be clinically-localized after standard diagnostic evaluation (eg chest x-ray, bone scan, CT scan, or MRI), who are at high-risk for pelvic lymph node metastases. It is not indicated for patients who are not at high risk.
Indium In 111 ProstaScint is also indicated as a diagnostic imaging agent in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease. The imaging performance of Indium In 111 ProstaScint following radiation therapy has not been studied.
The information provided by Indium In 111 ProstaScint imaging should be considered in conjunction with other diagnostic information. Scans that are positive for metastatic disease should be confirmed histologically in patients who are otherwise candidates for surgery or radiation therapy unless medically contraindicated. Scans that are negative for metastatic disease should not be used in lieu of histological confirmation.
ProstaScint is not indicated as a screening tool for carcinoma of the prostate nor for readministration for the purpose of assessment in response to therapy.